Executive Summary
The U.S. life sciences industry is facing a systemic shortage of regulatory affairs talent. The deficit is the product of three converging trends: a retirement wave at the senior level, hyper-expansion of regulatory work driven by MDR, IVDR, and AI/ML guidance, and an educational pipeline that has not scaled to match.
Today, an estimated 60,000 biopharma positions sit unfilled — and roughly 40% of senior regulatory affairs leaders are within a decade of retirement. The pipeline producing replacements is small: the most recent year on record shows only 522 master's degrees granted in regulatory science across the entire United States.
This paper frames the talent shortage not as an HR problem but as a strategic risk to the industry's ability to bring new medicines and devices to patients.
Key Findings
- 60,000 biopharma jobs estimated unfilled in the United States as of recent industry surveys.
- Approximately 40% of senior regulatory affairs leaders are within 10 years of retirement age.
- Only 522 master's degrees in regulatory science were granted in the U.S. in 2018 — the most recent year of comprehensive data.
- Hyper-expansion of regulatory work (MDR, IVDR, AI/ML guidance, cybersecurity expectations) has outpaced both hiring and training.
- The deficit compounds: each unfilled position increases the load on remaining staff and accelerates attrition.
Read the full analysis
The full white paper — including methodology, source citations, and detailed analysis of each finding — is available as a downloadable PDF.